Powder: -20°C for 3 years | In solvent: -80°C for 1 year
COX-2-IN-31 (compound 7b) is an orally active dual inhibitor targeting COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). Additionally, it inhibits the activity of transmembrane hCA IX (Ki=48.9 nM) and hCA XII (Ki=5.8 nM). This compound demonstrates anti-inflammatory and analgesic activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | COX-2-IN-31 (compound 7b) is an orally active dual inhibitor targeting COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). Additionally, it inhibits the activity of transmembrane hCA IX (Ki=48.9 nM) and hCA XII (Ki=5.8 nM). This compound demonstrates anti-inflammatory and analgesic activity [1]. |
Targets&IC50 | COX-2:60 nM, COX-1:12.5 μM |
In vitro | In the carbonic anhydrase inhibition assay, COX-2-IN-31 (compound 7b) effectively inhibited hCA IX and XII with Kᵢ values within the nanomolar range (48.9 nM and 5.8 nM) [1]. |
In vivo | COX-2-IN-31 (compound 7b) administered orally at a single dose of 10 mg/kg demonstrated analgesic activity by significantly reducing the number of writhing episodes in mice [1]. The same dosing regimen resulted in a notable decrease in paw edema height in carrageenan-induced rat paw edema tests [1]. Moreover, COX-2-IN-31 exhibited safety in the gastric tissues of albino male rats at this dosage level [1]. |
Molecular Weight | 400.41 |
Formula | C17H16N6O4S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
COX-2-IN-31 Immunology/Inflammation Neuroscience COX inhibitor inhibit